Indications for Pulmonary Valve Replacement in Repaired Tetralogy of Fallot
The Quest Continues

Tal Geva, MD

Pulmonary valve replacement (PVR) is increasingly used to treat the chronic volume overload from pulmonary regurgitation. The procedure can be performed by a transcatheter technique or surgically, using one of the many available bioprosthetic valves. The procedural mortality is low, usually <1%, but not negligible. Importantly, the functional integrity of all available bioprosthetic valves deteriorates over time, typically requiring repeat valve replacement within 10 years. The early results of PVR have been well described by several groups, painting a consistent picture characterized by resolution or marked reduction of pulmonary regurgitation, 30% to 40% reduction in RV end-diastolic and end-systolic volumes, unchanged RV ejection fraction, slightly increased left ventricular size with unchanged ejection fraction, decrease in RV systolic pressure in those with preprocedural RVOT obstruction, and consistent improvement in New York Heart Association functional class without a clear change in objective exercise parameters or arrhythmia burden. However, despite numerous investigations on timing, indications, techniques, and results of PVR, large gaps in knowledge persist on how best to manage these patients. To date, it remains unknown whether PVR reduces arrhythmia burden or improves survival in this population.

In this issue of Circulation, Frigiola et al describe the outcomes of 1085 consecutive patients with TOF managed at the Great Ormond Street Hospital for Children from 1964 to 2009. In addition to confirming that the mortality rate in this population is 4-fold higher than that of the general population and that the burden of morbidity is substantial, the investigators shed light on a long-neglected segment of this population, those with good late clinical outcomes. The study adds an important piece to the puzzle by characterizing the cardiac phenotype of patients defined by the authors as having “good outcomes”: those who reached 35 years of age without PVR, were asymptomatic, and had normal exercise tolerance. From a sample of 50 randomly selected patients without PVR who were invited to undergo detailed evaluation by echocardiography, cardiovascular magnetic resonance, and exercise testing, 14 fulfilled the above criteria for good late outcomes. Not surprisingly, these patients had a nearly normal right-sided heart structure and function, including at most mild RVOT obstruction, normal pulmonary valve annulus diameter, no more than mild to moderate pulmonary regurgitation, high-normal or minimally dilated RV, no RVOT aneurysm, and normal RV systolic function. The authors speculate that patients with this cardiac phenotype may not require additional interventions such as PVR and, hence, their primary repair can be considered “definitive.”

DOI: 10.1161/CIRCULATIONAHA.113.005878

The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

From the Department of Cardiology, Boston Children’s Hospital, Boston, MA, and Department of Pediatrics, Harvard Medical School, Boston, MA.

Correspondence to Tal Geva, MD, Department of Cardiology, Children’s Hospital Boston, 300 Longwood Ave, Boston, MA 02115. E-mail tal.geva@cardio.chboston.org


Circulation is available at http://circ.ahajournals.org

1855
These results and inferences must be viewed cautiously. The cohort studied by Frigiola et al.\textsuperscript{14} comprises only patients with “simple” TOF; that is, those with patent RVOT. Patients with more complex forms such as those with pulmonary atresia and other anatomic variants or associated anomalies were excluded. Therefore, the burden of residual disease and excess mortality reported in their article depicts a best-case scenario, with higher rates of morbidity and mortality expected when high-risk groups are included. Furthermore, among the small random sample of “ideal” TOF patients who were invited for further evaluation, we do not know how many declined participation and whether those who underwent further testing represent the broader cohort of patients who are asymptomatic and did not require cardiac interventions during follow-up. Moreover, we do not know whether these patients are at risk for developing late cardiac complications such as atrial flutter/fibrillation, ventricular tachycardia, or ventricular dysfunction. It is therefore prudent to continue to view repaired TOF as a lifelong disease that requires careful monitoring.

Despite these limitations, the study by Frigiola et al.\textsuperscript{14} provides useful information that highlights both ends of the disease spectrum and stimulates the ongoing discussion on timing and indications for PVR. Their findings confirm that a substantial proportion of adolescents and adults with repaired TOF receive PVR and that the frequency of the procedure increases as patient age rises. Notably, even among the small selected group of patients free of PVR, fewer than one third fulfilled the authors’ criteria for good outcome. This raises the question of whether the remaining patients should have undergone earlier PVR and whether such a management strategy would have resulted in better outcomes. The authors correctly note the lack of consensus regarding optimal timing of PVR and comment that their study does not directly address this question; however, coupled with the observation that PVR is the most frequently performed surgical procedure in adults with congenital heart disease in the United Kingdom, their findings underscore the importance of fine-tuning the indications for PVR in this population.

Despite the lack of consensus and the many persisting gaps in knowledge, the question of when to recommend PVR is a dilemma that confronts clinicians with increasing frequency. The Table provides a set of possible recommendations based on the author’s interpretation of the current literature. These recommendations, which do not represent the opinion of any institution or professional society, are based on the available evidence gleaned from studies that analyzed pre-PVR markers of post-PVR normalization of ventricular size or function. Little or no information is currently available to inform us about ventricular performance late after PVR, pre-PVR risk factors for post-PVR arrhythmias, exercise intolerance, or mortality. Furthermore, we have no information on how to apply pre-PVR risk factors to different anatomic or surgical phenotypes. We also do not know whether therapeutic interventions designed to modify these risk factors will, in fact, translate into a clinical benefit. With these limitations in mind, the guidelines outlined in the Table are meant to serve as a starting point for a discussion within our field and as a stimulus for future investigations designed to shed new light on areas where data are lacking.\textsuperscript{15–20}

<table>
<thead>
<tr>
<th>Indications</th>
<th>Supporting References</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Asymptomatic patients with ≥2 of the following criteria:</td>
<td></td>
</tr>
<tr>
<td>a. RV end-diastolic volume index &gt;150 mL/m(^2) or z score &gt;4</td>
<td>10, 12</td>
</tr>
<tr>
<td>In patients whose body surface area falls outside published normal data: RV/LV end-diastolic volume ratio &gt;2</td>
<td></td>
</tr>
<tr>
<td>b. RV end-systolic volume index &gt;80 mL/m(^2)</td>
<td>11, 13</td>
</tr>
<tr>
<td>c. RV ejection fraction &lt;47%</td>
<td>11, 15, 16</td>
</tr>
<tr>
<td>d. LV ejection fraction &lt;55%</td>
<td>11, 15, 16</td>
</tr>
<tr>
<td>e. Large RVOT aneurysm</td>
<td>17, 18</td>
</tr>
<tr>
<td>f. QRS duration &gt;160 ms</td>
<td>11</td>
</tr>
<tr>
<td>g. Sustained tachyarrhythmia related to right-sided heart volume load</td>
<td>6</td>
</tr>
<tr>
<td>h. Other hemodynamically significant abnormalities:</td>
<td></td>
</tr>
<tr>
<td>• RVOT obstruction with RV systolic pressure ≥0.7 systemic</td>
<td>19</td>
</tr>
<tr>
<td>• Severe branch pulmonary artery stenosis (&lt;30% flow to affected lung) not amenable to transcatheter therapy</td>
<td>19</td>
</tr>
<tr>
<td>• Greater than or equal to moderate tricuspid regurgitation</td>
<td>19</td>
</tr>
<tr>
<td>• Left-to-right shunt from residual atrial or ventricular septal defects with pulmonary-to-systemic flow ratio ≥1.5</td>
<td>19</td>
</tr>
<tr>
<td>• Severe aortic regurgitation</td>
<td>19</td>
</tr>
<tr>
<td>II. Symptomatic patients fulfilling ≥1 of the quantitative criteria detailed above. Examples of symptoms and signs include:</td>
<td></td>
</tr>
<tr>
<td>a. Exercise intolerance not explained by extracardiac causes (eg, lung disease, musculoskeletal anomalies, genetic anomalies, obesity), with documentation by exercise testing with metabolic cart (≥70% predicted peak (\dot{V}O_2) for age and sex not explained by chronotropic incompetence)</td>
<td>19</td>
</tr>
<tr>
<td>b. Signs and symptoms of heart failure (eg, dyspnea with mild effort or at rest not explained by extracardiac causes, peripheral edema)</td>
<td>19</td>
</tr>
<tr>
<td>c. Syncope attributable to arrhythmia</td>
<td>19</td>
</tr>
<tr>
<td>III. Special considerations:</td>
<td></td>
</tr>
<tr>
<td>a. Because of higher risk of adverse clinical outcomes in patients who underwent TOF repair at ≥3 years of age, PVR may be considered if they fulfill ≥1 of the quantitative criteria in section I</td>
<td>16</td>
</tr>
<tr>
<td>b. Women with severe PR and RV dilatation or dysfunction may be at risk for pregnancy-related complications. Although no evidence is available to support benefit from pre pregnancy PVR, the procedure may be considered if fulfilling ≥1 of the quantitative criteria in section I</td>
<td>20</td>
</tr>
</tbody>
</table>

LV indicates left ventricular; PR, pulmonary regurgitation; PVR, pulmonary valve replacement; RV, right ventricular; RVOT, right ventricular outflow tract; and TOF, tetralogy of Fallot.

The study by Frigiola et al.\textsuperscript{14} raises intriguing questions about our ability to identify patients with good outcomes late after TOF repair and, conversely, those at risk of poor outcomes. Simultaneously, though, the authors illustrate that even in a center with a large patient volume, our current ability to prognosticate remains poor, as highlighted by the 2
patients who were included in the good outcome group only to require subsequent PVR. Furthermore, as illustrated above, many controversies about optimal management of this growing population remain contentious. Thus, further progress in resolving these disagreements will only be achieved through large multicenter collaborative studies. Ideally, this will be performed with standardized, prospectively acquired clinical, imaging, exercise, electrocardiographic, and laboratory data. Such a large multicenter investigation would allow us to create an evidence-based consensus on the optimal timing and indications for PVR, as well as for refinement of surgical techniques. A collaborative endeavor such as that will help to overcome the relatively short duration of time that the procedure has been performed routinely (less than a decade in many institutions), the low rate of hard outcomes (eg, death, resuscitated cardiac arrest, sustained ventricular tachycardia), the reliance on surrogate outcomes of unclear clinical importance, and the ongoing evolution in treatment options. Such a prospective multicenter study would help generate hypotheses on optimal management that can then be tested in future randomized clinical trials.

Sources of Funding
This work was supported in part by National Institutes of Health/ National Heart, Lung, and Blood Institute grant 1 R01 HL089269-01A2 and by the Higgins Family Noninvasive Research Fund.

Disclosures
Dr Geva is a Screening Committee member, Native Transcatheter Pulmonary Valve Study, Medtronic.

References

Key Words: Editorials ■ magnetic resonance imaging ■ pulmonary valve ■ tetralogy of Fallot ■ ventricular dysfunction, right
Indications for Pulmonary Valve Replacement in Repaired Tetralogy of Fallot: The Quest Continues
Tal Geva

_Circulation_. 2013;128:1855-1857; originally published online September 24, 2013; doi: 10.1161/CIRCULATIONAHA.113.005878

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/128/17/1855

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/